

# Gary M Ansel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7474072/publications.pdf>

Version: 2024-02-01

51  
papers

2,082  
citations

361413

20  
h-index

265206

42  
g-index

51  
all docs

51  
docs citations

51  
times ranked

1792  
citing authors

#	ARTICLE	IF	CITATIONS
1	Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery. <i>Circulation</i> , 2016, 133, 1472-1483.	1.6	426
2	Sustained Safety and Effectiveness of Paclitaxel-Eluting Stents for Femoropopliteal Lesions. <i>Journal of the American College of Cardiology</i> , 2013, 61, 2417-2427.	2.8	307
3	Mortality Not Correlated With Paclitaxel Exposure. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2550-2563.	2.8	195
4	Safety and effectiveness of the INVATEC MO.MAA® proximal cerebral protection device during carotid artery stenting: Results from the ARMOUR pivotal trial. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 76, 1-8.	1.7	194
5	Stellarex Drug-Coated Balloon for Treatment of Femoropopliteal Disease. <i>Circulation</i> , 2017, 136, 1102-1113.	1.6	175
6	A Structured Review of Antithrombotic Therapy in Peripheral Artery Disease With a Focus on Revascularization. <i>Circulation</i> , 2017, 135, 2534-2555.	1.6	136
7	Drug-coated balloon treatment for lower extremity vascular disease intervention: an international positioning document. <i>European Heart Journal</i> , 2016, 37, 1096-1103.	2.2	73
8	Percutaneous Retrograde Tibial Access in Limb Salvage. <i>Journal of Endovascular Therapy</i> , 2003, 10, 614-618.	1.5	53
9	Paclitaxel-Coated Zilver PTX Drug-Eluting Stent Treatment Does Not Result in Increased Long-Term All-Cause Mortality Compared to Uncoated Devices. <i>CardioVascular and Interventional Radiology</i> , 2020, 43, 8-19.	2.0	47
10	Evolving Modalities for Femoropopliteal Interventions. <i>Journal of Endovascular Therapy</i> , 2009, 16, 1182-1197.	1.5	42
11	One-Year Results of the LIBERTY 360 Study: Evaluation of Acute and Midterm Clinical Outcomes of Peripheral Endovascular Device Interventions. <i>Journal of Endovascular Therapy</i> , 2019, 26, 143-154.	1.5	35
12	Directional atherectomy before paclitaxel coated balloon angioplasty in complex femoropopliteal disease: The VIVA REALITY study. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, 549-558.	1.7	33
13	Helical Centerline Stent Improves Patency. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	3.9	30
14	One-Year Analysis of the Prospective Multicenter SENTRY Clinical Trial: Safety and Effectiveness of the Novate Sentry Bioconvertible Inferior Vena Cava Filter. <i>Journal of Vascular and Interventional Radiology</i> , 2018, 29, 1350-1361.e4.	0.5	29
15	Functional and clinical outcomes of nitinol stenting with and without abciximab for complex superficial femoral artery disease: A randomized trial. <i>Catheterization and Cardiovascular Interventions</i> , 2006, 67, 288-297.	1.7	28
16	Paclitaxel exposure: Long-term safety and effectiveness of a drug-coated balloon for claudication in pooled randomized trials. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 1087-1099.	1.7	23
17	Clinical results for the training-phase roll-in patients in the intracoil femoralpopliteal stent trial. <i>Catheterization and Cardiovascular Interventions</i> , 2002, 56, 443-449.	1.7	22
18	Full Drug-Eluting Stent Jacket: Two-Year Results of a Single-Center Experience With Zilver PTX Stenting for Long Lesions in the Femoropopliteal Arteries. <i>Journal of Endovascular Therapy</i> , 2018, 25, 295-301.	1.5	22

#	ARTICLE	IF	CITATIONS
19	Drug-Coated Balloon Treatment of Femoropopliteal Lesions Typically Excluded From Clinical Trials: 12-Month Findings From the IN.PACT Global Study. <i>Journal of Endovascular Therapy</i> , 2018, 25, 673-682.	1.5	21
20	The LIBERTY study: Design of a prospective, observational, multicenter trial to evaluate the acute and long-term clinical and economic outcomes of real-world endovascular device interventions in treating peripheral artery disease. <i>American Heart Journal</i> , 2016, 174, 14-21.	2.7	20
21	Patient-level meta-analysis of 999 claudicants undergoing primary femoropopliteal nitinol stent implantation. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, 1250-1256.	1.7	20
22	A Review of Antithrombotic Therapy and the Rationale and Design of the Randomized Edoxaban in Patients With Peripheral Artery Disease (ePAD) Trial Adding Edoxaban or Clopidogrel to Aspirin After Femoropopliteal Endovascular Intervention. <i>Journal of Endovascular Therapy</i> , 2015, 22, 261-268.	1.5	16
23	Final Two-Year Outcomes for the Sentry Bioconvertible Inferior Vena Cava Filter in Patients Requiring Temporary Protection from Pulmonary Embolism. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, 221-230.e3.	0.5	15
24	Percutaneous Endovascular Aortic Aneurysm Repair for Abdominal Aortic Aneurysm. <i>Current Cardiology Reports</i> , 2018, 20, 79.	2.9	14
25	Three-Year Outcomes From the LIBERTY 360 Study of Endovascular Interventions for Peripheral Artery Disease Stratified by Rutherford Category. <i>Journal of Endovascular Therapy</i> , 2021, 28, 262-274.	1.5	14
26	Carotid Artery Stenting in Asymptomatic Carotid Artery Stenosis. <i>Journal of the American College of Cardiology</i> , 2020, 75, 648-656.	2.8	12
27	Drug-Coated Balloon Treatment of Femoropopliteal Lesions for Patients With Intermittent Claudication and Ischemic Rest Pain. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007730.	3.9	10
28	The Use of Femoropopliteal Stent-Grafts for Critical Limb Ischemia. <i>Techniques in Vascular and Interventional Radiology</i> , 2005, 8, 140-145.	1.0	9
29	Carotid stenting with embolic protection: evolutionary advances. <i>Expert Review of Medical Devices</i> , 2008, 5, 427-436.	2.8	7
30	Design Strategies for Global Clinical Trials of Endovascular Devices for Critical Limb Ischemia (CLI) – A Joint USA-Japanese Perspective. <i>Circulation Journal</i> , 2018, 82, 2233-2239.	1.6	7
31	Prediction Model for Freedom from TLR from a Multi-study Analysis of Long-Term Results with the Zilver PTX Drug-Eluting Peripheral Stent. <i>CardioVascular and Interventional Radiology</i> , 2021, 44, 196-206.	2.0	7
32	Characteristics and Outcomes of Patients With Diabetes Mellitus Undergoing Peripheral Vascular Intervention for Infrainguinal Symptomatic Peripheral Artery Disease. <i>Vascular and Endovascular Surgery</i> , 2021, 55, 124-134.	0.7	7
33	The heart of medicine and the smokescreen of the randomized trial of off-label use of vascular devices. <i>Catheterization and Cardiovascular Interventions</i> , 2008, 72, 998-1002.	1.7	6
34	A Quantitative Angiographic Comparison of Restenotic Tissue Following Placement of Drug-Eluting Stents and Bare Metal Stents in Symptomatic Patients With Femoropopliteal Disease. <i>Journal of Endovascular Therapy</i> , 2017, 24, 499-503.	1.5	6
35	The Clinical Rationale for the Sentry Bioconvertible Inferior Vena Cava Filter for the Prevention of Pulmonary Embolism. <i>International Journal of Vascular Medicine</i> , 2019, 2019, 1-15.	1.0	5
36	Zilver PTX RCT mortality analysis: no difference in long-term mortality rate for Zilver PTX drug-eluting stent compared to PTA/BMS. <i>CVIR Endovascular</i> , 2019, 2, 25.	1.1	4

#	ARTICLE	IF	CITATIONS
37	Keep out of jail: The reason to limit stent usage for the common femoral artery bifurcation. Catheterization and Cardiovascular Interventions, 2013, 81, 1042-1042.	1.7	3
38	The impact of chronic kidney disease on outcomes following peripheral vascular intervention. Clinical Cardiology, 2020, 43, 1308-1316.	1.8	3
39	Prevalence and predictors of elevated central venous pressure and obstructive sleep apnea in patients with lower extremity chronic venous disease. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2020, 8, 775-782.	1.6	3
40	Stents (grafting) should be the primary treatment for symptomatic superficial femoral artery disease. Catheterization and Cardiovascular Interventions, 2007, 69, 886-889.	1.7	1
41	Patterns of restenosis for the <scp>SFA</scp>: The second step on a long journey. Catheterization and Cardiovascular Interventions, 2017, 90, 647-647.	1.7	1
42	Drug-coated balloons versus drug-eluting stents in the femoropopliteal artery: comparing apples to oranges?. Journal of Cardiovascular Surgery, 2019, 60, 456-459.	0.6	1
43	Tibial intervention; no fear!. Catheterization and Cardiovascular Interventions, 2007, 70, 1040-1040.	1.7	0
44	Do not rock the BOAT: The latest atherectomy device improvement trial. Catheterization and Cardiovascular Interventions, 2014, 84, 245-245.	1.7	0
45	Treating on the edge. Catheterization and Cardiovascular Interventions, 2015, 86, 499-500.	1.7	0
46	The Italian stallions of <scp>CLI</scp> â€œvalue careâ€•delivery. Catheterization and Cardiovascular Interventions, 2017, 89, 921-922.	1.7	0
47	Pedal access: Put the â€œpedal to the metalâ€•or drive with caution?. Catheterization and Cardiovascular Interventions, 2019, 93, 1315-1316.	1.7	0
48	EDITORIAL: The Bias of Seeing What You Look For. Cardiovascular Revascularization Medicine, 2020, 21, 108-109.	0.8	0
49	Time for pulmonary embolism alert. Catheterization and Cardiovascular Interventions, 2021, 97, 1438-1439.	1.7	0
50	The Role of Drug-coated Balloons in Infrapopliteal Intervention. US Cardiology Review, 2012, 9, 112-114.	0.5	0
51	Mechanical thrombectomy in peripheral arterial interventions. Journal of Invasive Cardiology, 2004, 16, 10S-14S; quiz 14S-15S.	0.4	0